ARDX — ARDELYX, INC.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1437402 ·
Last close
$3.41
Market Cap
$880.42M
52W High
$8.40
52W Low
$3.33
ADV30
3,980,884
Next earnings
2026-10-29

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Jun 2026 120,877,000 115,118,000 -12,425,000 -16,721,000 575,894,000 97,191,000 426,881,000
Mar 2026 94,473,000 89,662,000 -32,793,000 -37,605,000 504,507,000 31,209,000 355,885,000
Dec 2025 125,215,000 114,366,000 5,099,000 -407,000 501,604,000 67,999,000 334,655,000
Sep 2025 110,329,000 106,347,000 4,668,000 -969,000 486,170,000 42,715,000 331,890,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-17,320,000
Investing CF
$-34,067,000
Financing CF
$58,533,000
CapEx
$-599,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.22
As of
2026-08-09

Balance + Analyst (yfinance extras)

Retained Earnings
$-1,001,265,000
Inventory
$25,858,000
Receivables
$100,352,000
ST Investments
$184,639,000
EBIT TTM
$-26,774,000
Pretax Income TTM
$-55,475,000
Interest Exp TTM
$28,701,000
Analysts
10

Yahoo Snapshot (yfinance, live)

Total Revenue
$450,894,016
EBITDA
$-32,106,000
Free Cash Flow
$20,468,000
Enterprise Value
$892,768,512
Total Cash
$281,830,016
Total Debt
$282,507,008
Shares Out
258,187,572
Trailing EPS
$-0.23
Book Value
$0.60
ROE
-38.6%
ROA
-4.2%
Div Yield
—

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 407,320,000 -40,977,000 -61,599,000 501,604,000 334,655,000 166,949,000 -42,483,000
Dec 2024 333,615,000 -27,950,000 -39,136,000 435,754,000 262,465,000 173,289,000 -44,809,000
Dec 2023 124,456,000 -63,276,000 -66,067,000 297,579,000 130,763,000 166,816,000 -89,717,000
Dec 2022 52,158,000 -63,759,000 -67,207,000 190,066,000 91,737,000 98,329,000 -70,044,000

TTM Snapshot

Revenues TTM
$172,355,000
NetIncome TTM
$-41,953,000
OpCashFlow TTM
$0
Assets (Latest)
$501,604,000
Forward EPS
$0.30

Max Pain — expiry 2027-01-15 (volume-derived — Yahoo OI feed degraded)

max pain strike: $4.00 · spot: $3.41 · call volume: 1,056 · put volume: 10,087
Expected Move to 2027-01-15: ±$1.05 (30.79%) — implied range $2.36 – $4.46 · ATM straddle on $3.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
CYRX Cryoport, Inc. $880.28M $17.38 —
TBPH Theravance Biopharma, Inc. $884.18M $17.03 —
ANL Adlai Nortye Group Ltd. $904.51M $15.40 —
JBIO Jade Biosciences, Inc. $912.62M $14.35 —
LXRX LEXICON PHARMACEUTICALS, INC. $845.42M $1.90 —

News headlines (Yahoo Finance, 1h cache)

Ardelyx Targets $500M Revenue This Year, Profitability by 2027
2026-09-21 08:02 · Yahoo
Hyperphosphatemia Market Insight, Epidemiology, and Market Forecast to 2036 Now Available — See Which Novel Mechanism Could Unseat Sevelamer as Phosphate Binders Face a Pill-Burden Reckoning
2026-09-08 14:45 · Yahoo
Ardelyx (ARDX) Cuts Guidance On Payer Hurdles As Fair Value Debate Heats Up
2026-08-22 18:08 · Yahoo
Ardelyx (ARDX) Q2 2026 Earnings Call Transcript
2026-08-14 00:44 · Yahoo
Ardelyx (ARDX) Posts Record Revenue, Is The Stock Still 70% Undervalued?
2026-08-07 15:13 · Yahoo
Compared to Estimates, Ardelyx (ARDX) Q2 Earnings: A Look at Key Metrics
2026-08-06 23:00 · Yahoo
Ardelyx Q2 Earnings Call Highlights
2026-08-06 22:04 · Yahoo
Ardelyx Reports Second Quarter 2026 Financial Results and Provides Business Update
2026-08-06 20:05 · Yahoo
Ardelyx to Report Second Quarter 2026 Financial Results on August 6, 2026
2026-07-23 12:01 · Yahoo
New Cross-Study Analysis from Spherix Global Insights Combines Physician, Dietitian and Patient Chart Data to Show Access Barriers Still Curbing Xphozah Uptake Ahead of the TDAPA Cliff
2026-07-29 14:46 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.